A Successful Model of Biosimilar Adoption in a Community Oncology Practice

2021 Year in Review - Biosimilars - Biosimilars

A comprehensive, team-based biosimilar adoption model in a community oncology practice demonstrated successful conversion from brand drugs to biosimilars that was associated with substantial cost-savings.

A comprehensive, team-based model for biosimilar adoption in a community oncology practice was described at the 2021 American Society of Clinical Oncology Annual Meeting.

A biosimilar adoption model developed by Texas Oncology in collaboration with McKesson Specialty Health utilized a comprehensive team approach that involved creation of educational materials on biosimilar conversion for patients and clinical staff, communication distributed to all personnel, and pharmacy-led review of all new orders and substitution with a biosimilar when applicable, as well as weekly identification of existing patients who would benefit from switching.

Applying the biosimilar adoption model from January 2020 to December 2020 led to a significant increase in the utilization of biosimilars, from 5% to 80% for rituximab, from 9% to 88% for bevacizumab, and from 8% to 74% for trastuzumab. The potential cost-savings due to conversion to these 3 biosimilars was $550 per administration for bevacizumab, $850 for trastuzumab, and $1400 for rituximab (based on Average Sales Price for a 70-kg patient). This translated to a cost reduction of $4 million or 21% in 1 month. The use of biosimilar multidose vials versus single-dose vials provided additional savings.

The authors demonstrated that a comprehensive team-based biosimilar adoption model was feasible and allowed successful conversion to biosimilars in a community oncology practice, and that it was associated with substantial cost-savings and ultimately lent itself to value-based cancer care.

Source: Wilfong LS, Dave N, Garey JS, et al. A successful model of biosimilar adoption in a community oncology practice. J Clin Oncol. 2021;39(suppl_15):6514.

Related Items
Adoption of Biosimilars—Why the Delay?
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Editorial, Biosimilars
Pharmacist-Driven Intervention Significantly Increases Biosimilar Adoption in Clinical Practice
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Biosimilars, Oncology Pharmacy Programs, ASCO Highlights
Comparing Single-Center Outcomes Between Reference and Biosimilar Granulocyte Colony-Stimulating Factor Drugs Used for Autologous Stem-Cell Mobilization
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Original Article, Biosimilars, Transplant
Oncologists’ Common Misconceptions About Biosimilars Revealed in a Recent Survey
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Biosimilars, ASCO Highlights
Comparative Efficacy and Safety of the Bevacizumab Biosimilar MIL60 versus Bevacizumab Reference in Patients with Advanced or Recurrent Nonsquamous NSCLC
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Same-Day Pegfilgrastim or PFG-cbqv Prophylaxis of Chemotherapy-Induced Neutropenia in Bendamustine plus Rituximab and CHOP±R Regimens in Patients with Lymphoma and CLL
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Same-Day Pegfilgrastim or Pegfilgrastim-cbqv Prophylaxis in miniCHOP Chemotherapy-Based Regimens for Non-Hodgkin Lymphoma
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Demographics and Clinical Characteristics of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-awwb in Real-World Oncology Clinics
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Impact of the Oncology Care Model on Use of Bone Supportive Medications, Antiemetics, and Growth Factors
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Cost-Efficiency Analysis of Conversion from Pegfilgrastim with On-Body Injector to Pegfilgrastim-jmdb to Provide Budget-Neutral Expanded Access to Prophylaxis and Treatment
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: